数据安全监查委员会向试验实施与进展负责人分享中期试验结果:一项叙述性综述
该叙述性综述系统检索多个数据库与主要健康研究利益相关方文献,分析数据安全监查委员会(DSMB)向非DSMB成员分享中期结果的方式与可接受性。纳入的162条文献中45%反对分享但承认例外,43.8%认为中期结果应保密仅限DSMB;六项调查中三项支持某种程度分享、三项不支持。文献无多数意见,纳入文献以个人观点为主而非证据。
要点
- 纳入162条文献中45%反对分享中期结果但承认存在例外情形。
- 43.8%的文献认为中期结果应保密并仅保留在DSMB内部。
- 六项调查中三项支持某种程度分享、三项不支持。
核心结论
- 文献中不存在多数意见,但最大一组文献表达的观点是中期结果应保密于DSMB,同时也承认存在可与非DSMB成员分享的情形。
- 需要更多研究,采用针对临床试验社区的详细调查,聚焦DSMB分享中期结果,以更好理解和指导DSMB中期结果分享实践。
研究设计与样本
- 采用系统检索策略对多个数据库和主要健康研究利益相关方进行叙述性综述。
- 纳入标准为全文中有关于与非DSMB成员分享中期试验结果的讨论。
- 纳入162条文献,其中79.6%(129/162)基于作者观点,16.7%(27/162)基于研究指南,3.7%(6/162)基于调查。
主要发现
- 最大一组文献73/162(45%)表达反对与非DSMB成员分享中期结果但承认例外的意见或论点。
- 紧随其后,71/162(43.8%)的纳入文献支持中期结果不应分享、应保密于DSMB的意见或论点。
- 六项调查中一半支持以某种能力分享,另一半三项不支持。
- 发现11种可能值得DSMB分享中期结果的情形,涉及DSMB常规实践、试验完成受威胁、患者安全、监管批准及其他情形。
- 在这些条件下分享的主要风险与引入试验偏倚相关。
关键数值与推荐
- 纳入文献中45%(73/162)反对分享但承认例外,43.8%(71/162)认为应保密仅限DSMB。
- 六项调查中三项支持某种程度分享,三项不支持。
- 发现11种可能值得分享中期结果的情形。
临床怎么用
- 原文未据此给出推荐。
局限性
- 纳入文献主要提供个人观点而非证据。
- 全球发现的调查聚焦于试验监查实践,缺乏关于具体分享什么、与谁分享及为何分享的详细信息。
- 需要更多研究,采用针对临床试验社区的详细调查,聚焦DSMB分享中期结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sharing interim data, results or result extrapolations is an important issue that can affect trial integrity. The different ways in which Data Safety Monitoring Boards (DSMBs) share interim results with non-DSMB members and the acceptability of such practices are poorly understood. Our objective was to undertake a narrative review specifically on what kind of interim results, if any, should be shared by the DSMB with non-DSMB members and why. METHODS: We conducted a narrative review using a systematic search strategy of several databases and major health research stakeholders. Literature was included if there was some discussion within the full text about sharing interim trial results with non-DSMB members. RESULTS: About 79.6% (129/162) of included citations were based on author's views, 16.7% (27/162) on research guidelines and 3.7% (6/162) on surveys. The largest group of citations, 73/162 (45%), expresses the opinion or argument against sharing interim results with exceptions. Trailing closely, 71/162 (43.8%) of the included citations support the opinion or argument that interim results should not be shared and should remain confidential with the DSMB. Half of the six surveys support sharing in some capacity, while the other three do not. Eleven circumstances were found that potentially warrant interim result sharing by the DSMB; they relate to (1) usual practices by DSMBs, (2) trial completion threatened, (3) patient safety, (4) regulatory approval and (5) other circumstances. Dominant risks for sharing under these conditions are associated with introducing trial bias. DISCUSSION/CONCLUSION: There was no majority view in the literature. However, the largest group of citations included express the idea that interim results should remain confidential with the DSMB but also acknowledge circumstances when they could be shared with non-DSMB members. Limitations of this review are that (1) the included literature predominately provides personal perspectives, not evidence, and (2) surveys found globally focus on trial monitoring practices lacking detailed information on what specifically to share, with whom and why. More research is needed with the use of a detailed survey of the clinical trial community focused on DSMB sharing interim results, to better understand and guide DSMB interim result sharing practices.
引用
- Borg Debono V, Mbuagbaw L, Thabane L, et al. Sharing interim trial results by the Data Safety Monitoring Board with those responsible for the trial's conduct and progress: a narrative review. Trials. 2017. PMID: 28279205. doi:10.1186/s13063-017-1858-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。